Geert R. D'Haens

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease

S. Vermeire, I. Lawrance, G. D'Haens, 2015, Alimentary pharmacology & therapeutics.

A Systematic Review of the Measurement of Endoscopic Healing in Ulcerative Colitis Clinical Trials: Recommendations and Implications for Future Research

G. D'Haens, W. Sandborn, B. Feagan, 2014, Inflammatory bowel diseases.

Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn’s Disease Patients: A Prospective Open-label Study

M. Eberhardson, P. Olofsson, G. Fiorino, 2023, Journal of Crohn's & colitis.

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

M. Vandervoort, G. D'Haens, W. Sandborn, 2015, Alimentary pharmacology & therapeutics.

Peripheral blood DNA methylation signatures predict response to vedolizumab and ustekinumab in adult patients with Crohn's disease: The EPIC-CD study

V. Joustra, I. Hageman, Geert R. D'Haens, 2024, medRxiv.

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

D. Laukens, G. D'Haens, W. Sandborn, 2017, Alimentary pharmacology & therapeutics.

Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis.

G. D'Haens, B. Lashner, S. B. Hanauer, 1993, The American journal of gastroenterology.